NSE ScannerHospitals & Diagnostics · Hospital/Nursing Management · NSE: MEDANTA · data 2026-10-31
Global Health Limited
In plain words
Price: 17.7% below its 52-week high of ₹1,544.
Delivery: 59.4% of traded shares were kept for delivery over the last 10 sessions, against 55.1% over the last 60.
Latest results: a net profit of ₹143 cr for the quarter ended Dec 2024 (+15.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹4,683 cr |
| Net profit (last 12 months) | ₹556 cr |
| Sales growth, 3 years (yearly) | 17.2% |
| Profit growth, 3 years (yearly) | 19.5% |
At a glance
Promoters 33.0% (unchanged in a year), pledged 0.0%, institutions 26.9%.
P/E 61.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 15.1%, ROCE 13.2%, operating margin 15.6%: how much profit it earns on the money it uses.
Debt/equity 0.30, Profit growth 19.5% and sales growth 17.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 19.5% a year over 3 years.
- Expensive on earnings (P/E 61.4).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY25)
MEDANTA Q3 FY25 results (consolidated figures, as filed on NSE).
Revenue was ₹943.44 crore, up 13.3% YoY and down 1.4% QoQ.
Net profit was ₹142.91 crore, up 15.6% YoY and up 9.2% QoQ.
Operating margin was 25.2% (25.5% a year ago).
EPS was ₹5.32, up 15.4% YoY and up 9.2% QoQ.
MEDANTA के Q3 FY25 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹943.44 करोड़; पिछले साल की तुलना में 13.3% की बढ़त, पिछली तिमाही की तुलना में 1.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹142.91 करोड़; पिछले साल की तुलना में 15.6% की बढ़त, पिछली तिमाही की तुलना में 9.2% की बढ़त।
ऑपरेटिंग मार्जिन: 25.2% (एक साल पहले 25.5%)।
EPS: ₹5.32; पिछले साल की तुलना में 15.4% की बढ़त, पिछली तिमाही की तुलना में 9.2% की बढ़त।
MEDANTAના Q3 FY25 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹943.44 કરોડ; ગયા વર્ષની સરખામણીએ 13.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.4% ઘટાડો.
ચોખ્ખો નફો: ₹142.91 કરોડ; ગયા વર્ષની સરખામણીએ 15.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 9.2% વધારો.
ઓપરેટિંગ માર્જિન: 25.2% (એક વર્ષ પહેલાં 25.5%).
EPS: ₹5.32; ગયા વર્ષની સરખામણીએ 15.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 9.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
20/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 8/30: Delivery 59.9% over the last 20 sessions vs 53.9% in the 40 before (1.11x); shares delivered per day 0.84x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 4 schemes hold it, about ₹119 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 14 Aug 26Dividend Dividend ₹0.5 (ex-date) +0.3% next session
- 22 Aug 25Dividend Dividend ₹0.5 (ex-date) +0.5% next session
- 4 Feb 25Results Q3 FY25 results: profit +15.6% YoY +10.6% next session
- 14 Nov 24Results Q2 FY25 results: profit +4.5% YoY +4.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2024 | ₹943 cr | ₹143 cr | +15.6% | 25.2% | 5.32 |
| Sept 2024 | ₹957 cr | ₹131 cr | +4.5% | 23.9% | 4.87 |
| Jun 2024 | ₹861 cr | ₹106 cr | +4.2% | 21.6% | 3.96 |
| Mar 2024 | ₹809 cr | ₹127 cr | +26.0% | 22.2% | 4.74 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 33.00% | 33.00% | 33.01% | 33.01% |
| Foreign institutions (FII) | 9.91% | 9.46% | 10.15% | 10.53% |
| Domestic institutions (DII) | 17.01% | 16.89% | 14.76% | 14.00% |
| Mutual funds | 15.97% | 16.03% | 13.91% | 13.12% |
| Retail investors | 3.62% | 3.71% | 3.94% | 3.97% |
| Number of shareholders | 1,35,371 | 1,40,531 | 1,47,390 | 1,51,241 |
Common questions
What was Global Health Limited's latest quarterly profit?
Global Health Limited reported a net profit of ₹143 cr for the quarter ended Dec 2024 (+15.6% on the same quarter a year earlier), on revenue of ₹943 cr.
How much do promoters hold in Global Health Limited?
Promoters held 33.00% of Global Health Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Global Health Limited debt-free?
Its latest reported debt-to-equity ratio is 0.3.
What is Global Health Limited's P/E ratio?
About 61.4, based on the last 12 months' earnings and a price of ₹1,270.3 (data 2026-10-31).
What is the 52-week high and low of Global Health Limited?
The 52-week high is ₹1,544 and the 52-week low is ₹956.
Mutual funds holding Global Health Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹119 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.74% | ₹102 cr |
| Nippon India Active Momentum Fund | Nippon India Mutual Fund | 2.36% | ₹14 cr |
| Nippon India Consumption Fund | Nippon India Mutual Fund | 0.13% | ₹3 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.90% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Global Health Limited | ₹1,270.3 | ₹34,122 cr | 61.4 | — | 15.1% | 13.2% | 0.3 | -7.6% |
| Max Healthcare Institute Ltd | ₹860 | ₹83,705 cr | 57.7 | — | 14.3% | 12.9% | 0.32 | -27.5% |
| Aster DM Quality Care Limited | ₹681.15 | ₹59,570 cr | 110.5 | — | 9.7% | 10.3% | 0.49 | -2.7% |
| Fortis Healthcare Ltd. | ₹768.15 | ₹58,117 cr | 55.3 | — | 11.1% | 12.3% | 0.35 | -27.2% |
| Narayana Hrudayalaya Ltd. | ₹1,720.2 | ₹35,144 cr | 42.8 | — | 19.8% | 14.5% | 1.29 | -4.4% |
| Krishna Institute of Medical Sciences Limited | ₹701.8 | ₹29,480 cr | 138.8 | — | 11% | 9.5% | 1.89 | -5.0% |
Compare MEDANTA with MAXHEALTH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDANTA in NSE Scanner →